CMC teams can align with Q5A(R2)’s updated guidance to shorten testing timelines and strengthen assurance of participant safety.
John Muganga
Advertisement
John Muganga is senior manager, Regulatory Affairs at ICON plc.
Articles by John Muganga
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Regeneron's Libtayo Earns CHMP Nod for Expanded EU Dosing
2
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
3
Biomarker Testing Gaps Can Stall Targeted Oncology Therapy, BMS’s Dr Pennell Says
4
Lilly’s Omvoh Reaches 50% One-Year Remission in Pediatric Ulcerative Colitis
5